Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01ZX1604B)
Received: 15 January 2021
Accepted: 13 July 2021
First Online: 11 August 2021
: G.N. received funding for research from Biotest AG. E.W., P.P., D.P., D.V., J.K., F.P., K.D., M.M., V.F., B.O., S.-M.W., S.A., T.H., B.S., C.D., L.E.S., N.S., M.R., D.B., A.D.G., C.G., M.L. and J.T declare no conflict of interest. M.W. received funding for research from Actelion, Bayer Health Care, Biotest AG, Boehringer Ingelheim, Noxxon, Pantherna, Quark Pharma, Vaxxilon, and for advisory from Actelion, Aptarion, Astra Zeneca, Bayer Health Care, Berlin Chemie, Biotest, Boehringer Ingelheim, Chiesi, Glaxo Smith Kline, Novartis, Noxxon, Pantherna, Teva and Vaxxilon. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.